A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and
immunogenicity of MRG002 as single agent in patients with HER2-positive unresectable locally
advanced or metastatic urothelium cancer.